Lupus erythematosuselike skin eruption after vemurafenib therapy

Journal of the American Academy of Dermatology

Volumn 71, Issue 4, 2014, Pages e159-e160

  Reinholz, Markus ^a   Berking, Carola ^a   Hermans, Cecilia ^a   Ruzicka, Thomas ^a   Braun Falco, Markus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MOMETASONE FUROATE; VEMURAFENIB; INDOLE DERIVATIVE; SULFONAMIDE;

AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CASE REPORT; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; LETTER; LUPUS ERYTHEMATOSUS LIKE SKIN ERUPTION; LYMPH NODE DISSECTION; METASTATIC MELANOMA; MULTIMODALITY CANCER THERAPY; NAUSEA; PATIENT EDUCATION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; IMMUNOHISTOCHEMISTRY; MELANOMA; NEEDLE BIOPSY; PATHOLOGY; RISK ASSESSMENT; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; SKIN TUMOR; TUMOR INVASION;

AGED; BIOPSY, NEEDLE; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FACIAL DERMATOSES; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; LUPUS ERYTHEMATOSUS, CUTANEOUS; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RISK ASSESSMENT; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84910152575     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.07.006     Document Type: Article

References (5)

1. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-9.
2. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
4. Flaherty KT, Puzanov I, KimKB, Ribas A,McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16.